You are here: Industry Insights > Eisai

News List

Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting PharmaSources.com
March 11, 2022
Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody...
Eisai Enters License Agreement with Roivant contractpharma
January 06, 2022
Grants the exclusive rights for global research, development, manufacture and sale of H3B-8800 to a subsidiary of Roivant Sciences Ltd
Investigational Alzheimer’s Disease Therapy Lecanemab Granted FDA Fast Track Designation Drugs
December 29, 2021
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today...
Eisai, Gilead Enter Exclusive Agreement for JAK Inhibitor Filgotinib in Asia contractpharma
December 22, 2021
Eisai obtains exclusive marketing right for filgotinib in South Korea, Taiwan, China, Hong Kong, S.A.R., China and Singapore and will take over manufacturing and marketing.
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad in Five ASEAN Countries b3cnewswire
September 07, 2021
Eisai Co., Ltd. and FUJI YAKUHIN CO., LTD. announced that they have concluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by FUJI YAKUHIN
FDA approves Keytruda plus Lenvima for advanced kidney cancer pharmatimes
August 13, 2021
The US Food and Drug Administration (FDA) has approved a combination of MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Eisai’s Lenvima (lenvatinib) for the first-line treatment of adult patients with advanced renal cell carcinoma ...
Eisai, Merck’s Drug Combo Approved for Advanced Endometrial Cancer contractpharma
July 26, 2021
LENVIMA plus KEYTRUDA demonstrates improvements in overall survival, reducing the risk of death by 32%, and progression-free survival by 40%.
Eisai, Biogen’s Lecanemab Gets Breakthrough Designation in AD contractpharma
July 21, 2021
Eisai Co., Ltd. and Biogen’s lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of Alzheimer's disease (AD), was granted Breakthrough Therapy designation from the FDA.
FDA grants breakthrough status to Eisai and Biogen’s Alzheimer’s drug pharmaceutical-technology
June 25, 2021
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Eisai and Biogen’s lecanemab (BAN2401) for Alzheimer’s disease (AD) treatment.
Alzheimer’s Drug Price Uproar Grows as U.S. Weighs Coverage firstwordpharma
June 23, 2021
The $56,000 annual price tag for Biogen and Eisai's Aduhelm is drawing increasing criticism ahead of a US government decision on reimbursement policies for the recently approved Alzheimer's disease drug, reported Bloomberg.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page